• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
Generic Name: Trans-Cinnamic Acid
Date Designated: 11/24/2020
Orphan Designation: Treatment of GM2 gangliosidosis
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Polaryx Therapeutics, Inc.
140 E. Ridgewood Avenue, Suite 415, South Tower
Paramus, New Jersey 07652
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.